Molecular profiling of ex vivo prostate cancer CAF models captures stromal heterogeneity and drug vulnerabilities
Open Access
- 6 November 2025
- journal article
- research article
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-10
Abstract
Cancer-associated fibroblasts (CAFs) are central architects of the prostate cancer (PCa) microenvironment, yet their phenotypic diversity and druggable vulnerabilities remain largely uncharted. Here, we present an integrative multi-omics characterization of primary ex vivo CAFs from seven treatment-naïve PCa patients. Using single-cell RNA sequencing (scRNA-seq), we uncover substantial transcriptional heterogeneity among CAFs, with distinct gene expression programs related to extracellular matrix remodeling, inflammation, immune modulation, and metabolic reprogramming. This phenotypic diversity was further supported by variable expression of canonical stromal markers, including FAP, SULF1, VIM, CAV1, and αSMA. Transcription factor network analysis revealed SOX, FOX, and STAT3 family members as key regulators of pro-tumorigenic CAF states. To probe therapeutic vulnerabilities, we performed high-throughput drug sensitivity and resistance testing (DSRT) across 396 oncology compounds. CAFs exhibited broad sensitivity to multikinase inhibitors, with dasatinib, midostaurin, and FGFR inhibitors (AZD4547, erdafitinib) emerging as top stromal-directed candidates. These findings underscore the plasticity of prostate CAFs and reveal actionable vulnerabilities, supporting the development of targeted stromal therapies to disrupt tumor-stroma interactions in PCa.Keywords
Funding Information
- Research Council of Finland (360437, 336449)
- Sigrid Juselius Foundation, Cancer Society of Finland
This publication has 39 references indexed in Scilit:
- New insights into Gremlin-1: A tumour microenvironment landscape re-engineer and potential therapeutic targetBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2025
- Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imagingAnnals of Nuclear Medicine, 2021
- Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small MoleculesJournal of Medicinal Chemistry, 2021
- The role of fibroblast activation protein in health and malignancyCancer and Metastasis Reviews, 2020
- Recent Global Patterns in Prostate Cancer Incidence and Mortality RatesEuropean Urology, 2020
- The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical AggressionCell, 2018
- Interleukin‐6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activationThe Prostate, 2018
- Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapyProteomics – Clinical Applications, 2014
- Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16BNature Medicine, 2012
- Human Prostate Fibroblasts Induce Growth and Confer Castration Resistance and Metastatic Potential in LNCaP CellsEuropean Urology, 2010